Axonics, Inc. AXNX recently achieved a milestone with the CE Mark approval of its fourth-generation rechargeable Sacral Neuromodulation (SNM) system, the R20. This groundbreaking device is set to ...

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...

Axonics Modulation Technologies, Inc. AXNX has presented a favorable outcome of its detailed one-year ARTISAN-SNM pivotal study at the joint scientific meeting of the American Urogynecologic Society ...

IRVINE, Calif., September 26, 2024--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics F15™ ...

IRVINE, Calif. - Axonics, Inc. (NASDAQ: AXNX), a medical technology firm specializing in bladder and bowel dysfunction treatments, has announced the receipt of CE Mark approval for its Axonics R20™ ...

Axonics Modulation Technologies (AXNX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...